Carmat Stock

Carmat EBIT Margin

Delisted

The EBIT Margin (Operating Margin) of Carmat (ALCAR.PA) as of Jul 29, 2026 is -712.60 %. In the previous year, EBIT Margin (Operating Margin) was -1,844.07 % — a change of -61.36% (higher).

EBIT Margin

-712.60 %

YoY

-61.36%

Last updated:

EBIT Margin (Operating Margin) of Carmat is 2026 -712.60 % . EBIT Margin (Operating Margin) of Carmat was 2025 -1,844.07 % . It decreases by -61.36% higher compared to the previous year.

For Carmat, the operating (EBIT) margin of -712.6% is up versus -404,566.7% a few years ago.

Access this data via the Eulerpool API

Carmat Stock analysis

What does Carmat do? Carmat SA is a French company that was founded in 2008 and is headquartered in Vélizy-Villacoublay, France. The company is involved in the development, manufacture, and sale of cardiovascular systems and artificial hearts. Carmat is a leader in developing technologies for the treatment of serious heart conditions and aims to provide highly innovative solutions for patients suffering from end-stage heart failure. The business model of Carmat is based on the development and commercialization of products that contribute to improving the quality of life for patients with serious heart conditions. The artificial hearts are made from biocompatible materials and can be implanted in human bodies. They can serve as a bridge to a heart transplant or even as a permanent solution for complete replacement of the natural heart. Carmat is divided into various divisions including research and development, production, sales, and marketing. The company's research and development department works on developing highly specialized technologies for the artificial hearts to enhance performance and reliability. The production department manufactures the artificial hearts and ensures a strictly controlled, sterile environment to ensure the highest quality of products. The sales and marketing team ensures that the artificial hearts are marketed and sold worldwide. Carmat currently offers the Carmat heart, which is considered a revolutionary product in the market. The heart is made from biocompatible materials and is produced through a strictly controlled process. It has been designed to maximize performance and reliability in an artificial heart solution. The artificial hearts are implanted in an elaborate and fully equipped operating room to ensure an optimal environment. Carmat has also formed partnerships with other companies and institutions to strengthen its research and development department and share knowledge and experience in the industry. This includes a partnership with Airbus, which supports the company in developing new technologies. Carmat also collaborates with medical facilities to test the artificial hearts and improve their performance. Overall, Carmat is a leading brand in the field of artificial hearts. The company aims to develop innovative products to improve the lives of people with heart failure. It has established itself as a reliable provider of artificial hearts in the market and strives to constantly improve its business activities to meet the growing demand for more effective treatment options for patients with heart problems. Carmat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Carmat stock

EBIT Margin (Operating Margin) of Carmat is -712.60 % in 2026.

Access this data via the Eulerpool API

Margins — Carmat

All Key Metrics — Carmat